Journals / Abant Tıp Dergisi / 2012 / Cilt: 1 - Sayı: 3

The pathogenesis of hypertension in end stage renal disease; the importance of the sodium and volume control

Son dönem böbrek yetmezliğinde hipertansiyon ve patogenezi; sodyum ve volüm kontrolünün önemi

Pages
177–181
Publication Date
2012-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Because sodium plays a key role in hypertension development among these population, salt restriction and additional ultrafiltration, if necessary, should be the mainstay of the antihypertensive treatment instead of antihypertensive drugs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hypertensions is a common clinical problem among patients with end stage renal failure.
📊
Key Findings & Data:Because physiopathology of hypertension in these patients is multifactoriel, complicated and less understood, effective blood pressure control usually can not be achieved in this population.
💡
Conclusion & Impact:Because sodium plays a key role in hypertension development among these population, salt restriction and additional ultrafiltration, if necessary, should be the mainstay of the antihypertensive treatment instead of antihypertensive drugs.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Son dönem böbrek yetmezliği · hipervolemi · sodyum

Abstract

Hypertensions is a common clinical problem among patients with end stage renal failure. Because physiopathology of hypertension in these patients is multifactoriel, complicated and less understood, effective blood pressure control usually can not be achieved in this population. Major two risk factors in the pathogenesis of hypertension in patients receiving hemodialysis treatment are extracellular volume and dietary sodium intake. Therapeutic targets should be determined according to etiopathogenesis. There is increasing number of evidence indicating sodium intake in patients with end stage renal failure is related to volume overload and hypertension. Because sodium plays a key role in hypertension development among these population, salt restriction and additional ultrafiltration, if necessary, should be the mainstay of the antihypertensive treatment instead of antihypertensive drugs.

Özet

Hipertansiyon, son dönem böbrek yetmezliği SDBY hastalarında oldukça yaygın görülen bir klinik problemdir. Buna karşın bu hastaların etkin kan basıncı kontrolünden çoğu zaman uzak olmasının önemli bir sebebi, bu hasta grubunda hipertansiyon fizyopatolojisinin karmaşık, multifaktoriyel ve az anlaşılmış olmasından kaynaklanmaktadır. Hemodiyaliz hastalarındaki hipertansiyonun patogenezinde majör risk faktörlerinden ikisi, artmış ekstrasellüler volüm ve sodyum alımıdır. Buradan yola çıkarak terapödik hedefin anahatları da bu etyopatogenez çerçevesinde belirlenmelidir. Bulgular SDBY hastalarında sodyum yüklenmesinin, volüm yüklenmesi ve hipertansiyonla paralel seyrettiğini düşündürmektedir. Bu durum sodyumun, hipertansiyon için kilit bir rol oynadığını ve tedavinin yönetiminde esas uğraşı alanının antihipertansif ilaç desteği değil, tuz kısıtlaması ve gereğinde ek ultrafiltrasyon desteğinin olması yönündeki mücadelenin merkezi rolünü düşündürmektedir.

🔖

Cite This Article

TEKÇE, H., AKTAŞ, G., KÜRŞAT, S. (2012). The pathogenesis of hypertension in end stage renal disease; the importance of the sodium and volume control. Abant Tıp Dergisi, Cilt: 1 - Sayı: 3, 177–181. https://ajindex.com/articles/449239

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Jimmy W, Tariq S, Allen R.N. Role of sodium and volume in the pathogenesis of hypertension in hemodialysis. Semi- nars in Dialysis 2000; 17: 260–264. Salem M. Hypertension in the hemodialysis population? High time for answers. Am J Kidney Dis 1999; 33: 592–594.
  2. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AKl, HEMO Study Group. Risk factors for hypertension in chronic he- modialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21: 280–288.
  3. Horl M, Horl W. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002; 39: 227–244.
  4. Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E, Ogundipe A, Weigel K, Smith MC. Factors associated with inadequate blood pressure control in hypertensive hemo- dialysis patients. Am J Kidney Dis 1999; 33: 498–506.
  5. Foley RN, Parfrey PS, Hartnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, mor- bidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379–1385.
  6. Grekas D, Bacharaki D, Goutzaridis N, Kasimatis E, Tourkan- tonis A. Hypertension in chronic hemodialysis patients: cur- rent view on pathophysiology and treatment. Clin Nephrol 2000; 3: 164–168.
  7. Leypoldt JK, Cheung AK, Delmez JA Gassman JJ, Levin NW, Lewis JA, Lewis JL, Rocco MV. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int 2002; 61: 266–275.
  8. Lins LE, Hedenborg G, Jacobson SH, Samuelson K, Tedner B, Zetterholm UB, Ljungqvist O. Blood pressure reduction during hemodialysis correlated to intradialytic changes in plasma volume. Clin Nephrol 1992; 37: 308–313.
  9. Tozawa M, Iseki K, Iseki C, Morita O, Yoshi S, Fukiyama K. Seasonal blood pressure and body weight variation in pa- tients on chronic hemodialysis. Am J Nephrol 1999; 19: 660–667.
  10. Blumberg A, Nelp WD, Hegstrom RM, Scribner BH. Extracel- luler volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet 1967; 2: 69– 73. Amico M, Locatelli F. Hypertension in dialysis: pathophysi- ology and treatment. J Nephrol 2002; 15: 438–445. Scribner BH. A personalized history of hemodialysis. Am J Kidney Dis 1990; 16: 511–519.
  11. Chazot C, Bergstrom J, Scribner BH: Blood pressure control in dialysis patients: the importance of the lag phenomenon. Am J Kidney Dis 1998; 32: 720–724.
  12. Ruffman K, Mandelbaum A, Bommer J, Schmidli M, Ritz E. Doppler echocardiographic findings in dialysis patients. Nephrol Dial Transplant 5: 426–431,1990 Charra B. Control of blood